How to use monoclonal antibodies for migraine in primary care
UC migraine expert featured in Medscape article
The University of Cincinnati's Vincent Martin told Medscape that every primary care clinician should know about monoclonal antibodies for preventing migraines that are changing the lives of patients.
"These should be primary care meds," said Martin, MD, professor in the Department of Internal Medicine in UC's College of Medicine and director of the Headache and Facial Pain Center at the University of Cincinnati Gardner Neuroscience Institute. Physicians using the calcitonin gene-related peptide (CGRP) monoclonal antibodies "can dramatically improve the quality of their migraine patients just by learning how to use this group of medications," he continued.
Martin said many of his patients who couldn't tolerate or had inadequate repsponses to conventional migraine medications are now doing very well with CGRP agents.
"The old, conventional preventive therapies took 1-3 months to work. In some instances, these medications can work in a week or less — their onset of action is much quicker," Martin said.
Featured photo at top of a woman with a headache. Photo/FG Trade/iStock.
Related Stories
The subtle changes in hearing you should never ignore
July 24, 2026
It’s easy to dismiss changes in hearing as minor. But as The Washington Post recently reported, these symptoms could also signal a medical emergency that many people don’t recognize — known as sudden sensorineural hearing loss, a rapid decline in hearing that occurs suddenly or over a few days.
UC experts say proper produce washing is key defense against Cyclospora
July 24, 2026
Hamilton County Public Health reports confirmed cases of cyclosporiasis, as concerns persist. Cyclospora is a parasite that can cause a stomach illness lasting days — sometimes even weeks. University of Cincinnati medical experts say it is usually linked to contaminated water or food, often fresh produce.
What are the options for male birth control?
July 24, 2026
Despite major advances in contraception during the past several decades, responsibility for pregnancy prevention falls largely on women. As recently reported in Endocrinology Advisor, a new generation of male contraceptive candidates is advancing into early- and mid-stage clinical trials.